The patient has a low likelihood of experiencing adverse events ranging from local irritation, allergic reactions, phlebitis, end-organ granuloma, tissue ischemia, pulmonary emboli, pulmonary dysfunction, pulmonary infarction, and toxicity.
Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject
Single-use Cartridge Syringe System by Hospira: Recall – Due to the Potential Presence of Particulate Matter
More from FDA News AlertsMore posts in FDA News Alerts »
- FDA In Brief: FDA Hosts Third Summit Focused on Reducing the Availability of Opioids Online
- Coronavirus (COVID-19) Update: September 17, 2021
- Federal Court Enters Consent Decree Against Florida Compounder, Prohibiting Manufacture and Distribution of Drugs Due to Insanitary Conditions
- Potential for False Positive Results with Abbott Molecular Inc. Alinity m SARS-CoV-2 AMP and Alinity m Resp-4-Plex AMP Kits – Letter to Clinical Laboratory Staff and Health Care Providers